Sitagliptin, the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program and complete a form using the information at the bottom of the page.
- Incretin mimetic drugs for type 2 diabetes
- FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes
- Information for Healthcare Professionals: Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet)